DMU2105 is primarily utilized in the field of pharmaceutical research and development. It is being investigated for its potential as a therapeutic agent, particularly in the treatment of certain types of cancer. Early-stage studies suggest that it may act as an inhibitor targeting specific pathways involved in tumor growth and proliferation. Researchers are exploring its efficacy in preclinical models to assess its ability to suppress cancer cell activity while minimizing effects on healthy cells. Additionally, DMU2105 is being studied for its pharmacokinetic properties to determine optimal dosing and delivery methods. Its application extends to drug discovery, where it serves as a lead compound for developing more potent and selective inhibitors. Ongoing research aims to validate its safety and effectiveness, paving the way for potential clinical trials in the future.